Percutaneous treatment of multivalve disease: severe aortic and mitral regurgitation. Complex patient, complex solution

Cardiovascular Revascularization Medicine: Interesting Cases Pub Date : 2025-08-19 DOI:10.1016/j.crmic.2025.100098

Alba Abril Molina , Manuel Villa Gil Ortega , José Eduardo López Haldón , Isabel Merino González , Carmen Federero Fernández , Almudena Aguilera Saborido , Ana López Suárez , Mónica Fernández Quero , Agustín Guisado Rasco , Rosa Cardenal Piris , José Francisco Díaz Fernández

{"title":"Percutaneous treatment of multivalve disease: severe aortic and mitral regurgitation. Complex patient, complex solution","authors":"Alba Abril Molina , Manuel Villa Gil Ortega , José Eduardo López Haldón , Isabel Merino González , Carmen Federero Fernández , Almudena Aguilera Saborido , Ana López Suárez , Mónica Fernández Quero , Agustín Guisado Rasco , Rosa Cardenal Piris , José Francisco Díaz Fernández","doi":"10.1016/j.crmic.2025.100098","DOIUrl":null,"url":null,"abstract":"<div><div>The case of a 77-year-old male with decompensated heart failure due to multivalve disease is presented: severe primary aortic regurgitation (tissue defect, without calcification) and severe mixed mitral regurgitation (functional and ruptured chordae tendineae). Due to severe left ventricle dysfunction and high surgical risk, a combined percutaneous treatment was performed successfully although very technically demanding (TAVI in TAVI and two Mitraclip devices).</div><div>Multivalvular disease is associated with worse prognosis, difficult diagnosis and therapeutic challenges.<sup>1</sup> Therefore, an individual assessment of each patient by a heart team, a comprehensive treatment planning and the experience and skill of the operators to handle any unforeseen issues are essential for success.</div></div>","PeriodicalId":100217,"journal":{"name":"Cardiovascular Revascularization Medicine: Interesting Cases","volume":"9 ","pages":"Article 100098"},"PeriodicalIF":0.0000,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular Revascularization Medicine: Interesting Cases","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2950275625000449","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

The case of a 77-year-old male with decompensated heart failure due to multivalve disease is presented: severe primary aortic regurgitation (tissue defect, without calcification) and severe mixed mitral regurgitation (functional and ruptured chordae tendineae). Due to severe left ventricle dysfunction and high surgical risk, a combined percutaneous treatment was performed successfully although very technically demanding (TAVI in TAVI and two Mitraclip devices).

Multivalvular disease is associated with worse prognosis, difficult diagnosis and therapeutic challenges.¹ Therefore, an individual assessment of each patient by a heart team, a comprehensive treatment planning and the experience and skill of the operators to handle any unforeseen issues are essential for success.

查看原文本刊更多论文

多瓣疾病的经皮治疗：严重的主动脉和二尖瓣反流。复杂的病人，复杂的解决方案

本文报告一位77岁男性多瓣膜疾病导致失代偿性心力衰竭的病例：严重的原发性主动脉反流（组织缺损，无钙化）和严重的混合性二尖瓣反流（功能和腱索破裂）。由于严重的左心室功能障碍和高手术风险，尽管技术要求很高（TAVI中的TAVI和两个Mitraclip装置），但经皮联合治疗成功。多瓣膜病预后差，诊断困难，治疗困难因此，心脏团队对每位患者的单独评估，全面的治疗计划以及操作人员处理任何不可预见问题的经验和技能对于成功至关重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cardiovascular Revascularization Medicine: Interesting Cases

自引率

0.00%

发文量